影响运动神经元疾病患者参与试验的因素
Emily Beswick1,2,3, Micheala Johnson1,2,3, Judith Newton1,2,3
1Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland.
Journal of neurology
|October 3, 2023
概括
运动神经元疾病 (MND) 患者有动力参加临床试验. 然而,老年人参与的可能性较低,这凸显了在MND研究中需要量身定制的招聘策略.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 患者招募 患者招募
背景情况:
- 运动神经元疾病 (MND) 是一种进展性神经退行性疾病,治疗选择有限.
- 神经学临床试验经常面临患者招募和保留方面的挑战.
- 运动神经元疾病系统性多臂随机适应试验 (MND-SMART) 旨在发现MND的疾病修饰药物.
研究的目的:
- 调查在MND临床试验中影响招募和留住MND临床试验的个人特定因素.
- 加强试验协议的设计,以改善参与者的参与.
主要方法:
- 120名MND患者填写了问卷,并收集了临床数据.
- 参与者参与MND-SMART试验的参与被评估在完成问卷后12个月.
- 统计分析,包括赔率比率,用于确定与参与相关的因素.
主要成果:
- 50%的参与者被随机分配到MND-SMART,78%的人表示有兴趣参与.
- 年龄较大显着与参与试验的可能性降低相关 (OR=0.92).
- 65%的随机参与者在一年后仍在试验中.
结论:
- 患有MND的个体表现出强烈的参与研究的意愿.
- 老年人代表了一个人口统计学群体,在MND临床试验中参与率明显较低.
- 未来的试验设计应包括探索参与者特征的研究,以优化招聘和保留.
相关概念视频
Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K


